Periocular Triamcinolone for Prevention of Macular Edema after Plaque Radiotherapy of Uveal Melanoma: A Randomized Controlled Trial

摘要: Objective To determine the efficacy and safety of periocular triamcinolone acetonide (40 mg) for prevention macular edema in patients undergoing plaque radiotherapy uveal melanoma. Design Prospective, randomized, controlled clinical trial. Participants Controls One-hundred sixty-three with newly diagnosed melanoma iodine 125 were entered into study. Fifty-five randomized to control group 108 group. Eighteen-month data available 143 (88%) 163 patients. Intervention Periocular injection mg 1 ml) at time 4 months 8 later. Optical coherence tomography was performed each patient evaluation. Main Outcome Measures tomography-evident edema, moderate vision loss, poor final visual acuity. Results occurred significantly less often compared up 18 after (hazard estimate, 0.45; 95% confidence interval, 0.19–0.70; P = 0.001). At 18-month follow-up, loss (loss 3 lines or more best-corrected acuity [BCVA]) severe (BCVA 0.039] 5% vs. 15% [ 0.048], respectively). Rates elevated intraocular pressure cataract progression similar both groups. Conclusions is beneficial reducing risk reduces these Financial Disclosure(s) The author(s) have no proprietary commercial interest any materials discussed this article.